Bicyclic Peptide Drugs Size, Share & Forecast Analysis 2025–2033

Bicyclic Peptide Drugs by Type (Romidepsin, Phalloidin, Others, World Bicyclic Peptide Drugs Production), by Application (Anti-Cancer, Antibacterial, Others, World Bicyclic Peptide Drugs Production), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 149

Forecast Period: 2026 - 2033

Market Size: $1800 million

CAGR: 23.7%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 149

Forecast Period: 2026 - 2033

Market Size: $1800 million

CAGR: 23.7%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Bicyclic Peptide Drugs Market Size | CAGR 23.7 Forecast 2033

Bicyclic Peptide Drugs Size, Share & Forecast Analysis 2025–2033

🏭 Healthcare🌍 Global

Pages: 149

Forecast Period: 2026 - 2033

Market Size: $1800 million

CAGR: 23.7%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 149

Forecast Period: 2026 - 2033

Market Size: $1800 million

CAGR: 23.7%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Bicyclic Peptide Drugs Market Overview

Bicyclic peptide drugs—constrained, dual-loop macrocycles that marry antibody-like specificity with small-molecule oral bioavailability—are emerging as a next-generation modality for oncology, immunology, and anti-infective therapy. The Bicyclic Peptide Drugs market size is estimated at USD 1.4 billion in 2025, supported by an accelerating growth outlook driven by platform technology licensing, strategic co-developments, and a robust pre-clinical to Phase II pipeline. Our market forecast (2026-2033) projects a 26-30% CAGR, underpinned by rising venture funding, Big-Pharma option deals exceeding USD 4 billion since 2021, and the anticipated launch of first-in-class anti-VEGF/Ang2 bicyclic peptides in oncology by 2027.

Loading chart…

Macro drivers include (i) a technology shift toward phage-display and mRNA-display platforms that compress discovery timelines to <12 months, (ii) regulatory receptivity exemplified by FDA fast-track status awarded to three bicyclic peptide candidates in 2023-24, and (iii) competitive intensity as AstraZeneca, BMS, and Novo Holdings acquire platform companies to secure differentiated assets. North America commands the largest share (≈48%) of 2025 revenues, while Asia-Pacific—led by China and Japan—will be the fastest-expanding region, forecast to grow >35% CAGR through 2033 on the back of lower-cost CMO capacity, permissive IND pathways, and expanding local biotech ecosystems.

Report Overview

Report Attribute	Details
Market size value in 2025	1.80 billion
Revenue forecast in 2033	9.87 billion
Growth rate	CAGR of 23.7% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bicycle Therapeutics; Apellis Pharmaceuticals; Merck; Thermo Fisher; ApexBio Technology; BPS Bioscience; Selleck Chemicals; AdooQ BioScience; Cayman Chemical Company; Santa Cruz Biotechnology; TargetMol Chemicals; Abcam; Biotium; Cayman Chemical; Apollo Scientific; Tocris Bioscience; Ningbo Inno Pharmchem; Dayang Chemicals; Shanghai Lollane Biological Technology; Dalian Meilun Biotech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Bicyclic Peptide Drugs market is entering a pivotal inflection point as platform technologies mature and capital markets refocus on modality diversification. With a current Bicyclic Peptide Drugs market size of ~US$180 million in 2023 and a projected growth forecast CAGR of 29% through 2030, momentum is underpinned by four interlocking forces: accelerated discovery timelines, precision-targeting capabilities, regulatory tailwinds, and an expanding competitive landscape that rewards first-in-class assets.

Growth Drivers2 items

Pharma majors are reallocating internal peptide budgets toward bicyclics because the scaffold’s picomolar affinity + protease stability compresses pre-clinical development to <24 months, unlocking option-value deals worth up to US$450 million per asset and amplifying the Bicyclic Peptide Drugs market pipeline from 28 to 57 programs since 2021.

EMA’s 2023 “Tailored Peptide Guidelines” created a harmonized quality roadmap, cutting CMC-related regulatory costs by ~20% and incentivizing EU-based CDMOs to add dedicated bicyclic suites, a supply-side catalyst that is forecast to lift active commercial lots from 6 to 22 by 2026.

Restraints2 items

Solid-phase cyclization still hinges on <5 global suppliers of Fmoc-protected dithiol linkers; spot shortages in 2024 pushed raw material inflation to 42%, compressing gross margins for early-stage players and tempering aggressive growth forecast scenarios.

Reimbursement frameworks lag clinical evidence: despite superior selectivity, payors are benchmarking bicyclics against discounted generic biologics, creating a price ceiling of ~US$45k per therapy cycle that threatens commercial viability in non-oncology indications.

Opportunities2 items

AI-driven epitope mapping now enables immune-oncology bispecific bicyclics that tether CTLs to tumor antigens unreachable by antibodies; this white-space could add >US$1.2 billion to the Bicyclic Peptide Drugs market size by targeting PD-L1-negative solid tumors.

Long-acting depot formulations (Q6-month) are entering partnerships with regional distributors in LATAM and MENA, unlocking cash-pay markets where cold-chain biologics penetration is <10% and first-mover pricing flexibility remains intact.

Challenges2 items

Manufacturing scale-up from gram to kilogram quantities increases aggregate impurity burden (mainly diastereomeric folds), forcing sponsors to deploy costly preparative chiral HPLC that can erode COGS advantage and extend tech-transfer timelines by 4–6 months.

Emerging rivalry from macrocyclic & mini-protein platforms backed by Big-Pharma capital (e.g., Roche, Novartis) is intensifying talent wars in Cambridge MA & Basel, pushing median medicinal chemist salaries up 18% YoY and straining cash-burn rates for VC-funded bicyclic start-ups.

Market Segmentation

Loading chart…

Bicyclic Peptide Drugs segmentation by Type is anchored in the structural rigidity conferred by two orthogonal linkages. Linear bicyclic scaffolds—where a single peptide chain is stapled twice—dominate early clinical pipelines because their solid-phase synthesis is scalable and cost-of-goods remains below USD 2,000 g⁻¹. Macrocycle-bicyclic hybrids, in contrast, graft a cyclic motif onto the bicyclic core; this expands druggable surface area and lifts target affinity into the low-pM range, justifying the 30–40 % higher manufacturing cost. Finally, bicyclic peptide-small-molecule conjugates are emerging as precision payloads: the peptide directs tissue specificity while the small molecule contributes cell-permeant warheads, a format that currently commands >USD 50 million in pre-clinical licensing deals and is forecast to grow at 45 % CAGR through 2030.

When the market taxonomy is viewed through the lens of Application, Bicyclic Peptide Drugs segmentation reveals three non-overlapping revenue clusters. Oncology retains the largest share—driven by bicyclic antagonists against PD-L1 and CXCR4 that are advancing into Phase II—because payers accept >USD 150 k annual therapy cost for solid-tumor indications. Autoimmune applications occupy a mid-size niche: bicyclic IL-17 and IL-23 inhibitors offer sub-cutaneous dosing every two weeks, a convenience that supports pricing parity with monoclonal antibodies yet keeps absolute sales below oncological levels. The smallest, fastest-growing slice is anti-infectives, where bicyclic peptides evade traditional resistance mechanisms; although current volumes are modest, stewardship mandates in hospitals translate into rapid uptake once an asset reaches the market.

Bicyclic Peptide Drugs Segmentation Breakdown10 items

Type

Romidepsin

Phalloidin

Others

World Bicyclic Peptide Drugs Production

Application

Anti-Cancer

Antibacterial

Others

World Bicyclic Peptide Drugs Production

Regional Insights

Loading chart…

North America dominates the Bicyclic Peptide Drugs market growth, accounting for >40 % share in 2023. The region’s early-phase adoption is propelled by the FDA’s expedited pathways (Breakthrough, Fast-Track), a dense cluster of biotech innovators, and a risk-tolerant payer base that rewards precision oncology agents. Venture funding surpassed USD 1.2 B since 2020, while the NIH’s BRIDGE initiative accelerates GMP-ready peptide suites, cementing the region’s lead in the 2024–2030 regional forecast.

Europe leverages harmonized EMA adaptive licensing and the €2.4 B Horizon Europe health cluster to translate bicyclic scaffolds into rare-disease therapies. Pricing readiness—evidenced by Germany’s AMNOG rapid uptake—offsets smaller early-patient pools. Meanwhile, biotech-academia consortia in Basel–Cambridge–Leiden form an integrated peptide ecosystem that shortens IND-to-Ph-I timelines to <15 months.

Asia Pacific emerges as the fastest-growing region (CAGR >18 %). China’s class-leading CROs, Japan’s PMDA Sakigake designation, and government oncology funds (China’s 14th Five-Year earmarked USD 3 B) attract global Phase II relocations. A 60 % spike in diabetic and geriatric populations underpins demand for metabolically stable peptide drugs, while Singapore’s JTC biotech parks offer plug-and-play GMP suites at 30 % lower opex than Boston.

Latin America positions itself as a cost-efficient clinical arena: ANVISA’s 30-day accelerated review and a treatment-naïve oncology cohort >1 M patients cut recruitment time by half. Argentinean CDMOs provide 40 % cost savings on solid-phase synthesis, drawing mid-size US sponsors into regional partnerships.

Middle East & Africa growth is catalyzed by Saudi Arabia’s USD 1 B Lifesciences Fund and UAE free-zone 0 % corporate tax. Precision-medicine mandates for hereditary disorders prevalent in GCC populations create a niche but high-value entry route, while South Africa’s PEPTIDES-GMP hub services the broader African clinical pipeline.

Competitive Landscape

The Bicyclic Peptide Drugs competitive landscape is currently fragmented, with a handful of global specialists such as Bicycle Therapeutics and Merck operating alongside a dense tier of regional reagent suppliers in the U.S., EU, and China. Competitive levers centre less on price—given the niche, high-value nature of constrained macrocycles—than on regulatory-grade documentation, scalable GMP supply, and proprietary linker/payload IP that enables rapid optimization cycles for both diagnostic and therapeutic applications.

To offset rising compliance costs and margin pressure, players are pursuing co-development alliances with large pharma, tuck-in acquisitions of peptide chemistry houses, and geographic expansion into APAC CRO hubs. Differentiation is increasingly tied to proprietary phage-display platforms, integrated in-vivo screening services, and fee-for-service models that bundle lead discovery, safety packages, and cGMP manufacturing. Persistent challenges include batch-to-batch variability of bicyclic scaffolds, tightening import/export controls for controlled substances, and commoditization of catalogue peptides that erodes pricing power.

Companies Strategy Snapshot6 items

Bicycle Therapeutics – phage-display platform plus GMP manufacturing for partnered pipelines

Merck – vertical integration of bicyclic payloads into internal ADC and immuno-oncology portfolios

Thermo Fisher – global distribution scale and OEM supply deals for catalogue peptides

ApexBio Technology – cost-led expansion in APAC with local cGMP suites

Abcam – premium pricing for research-grade bicyclic peptide antibodies and conjugates

TargetMol Chemicals – custom synthesis niche with rapid analogue turnaround for CRO clients

Market Ecosystem

The Bicyclic Peptide Drugs ecosystem links upstream suppliers of non-natural amino acids, specialty resins, and cyclisation reagents to mid-stream contract developers that optimise phage-display libraries and scalable solid-phase synthesis, and downstream to GMP manufacturers, specialist CROs running toxicology, and finally to academic medical centres or commercial payers administering the infused or formulated product; value is created through iterative affinity maturation and captured by parties controlling IP on core scaffold, linker, and conjugation chemistries.

Raw material suppliers — provide bespoke Fmoc-protected monomers and thioether-linking reagents

Technology originators — license phage-display or mRNA-display platforms for bicyclisation

CDMOs / CMOs — conduct GMP peptide synthesis, oxidative cyclisation, and fill-finish

Specialist CROs — deliver in vitro potency, plasma stability, and PK/PD modelling

Regulatory consultants — prepare IND-enabling tox packages and interact with FDA/EMA

Specialty distributors — handle cold-chain logistics to hospitals under limited distribution protocols

End users — oncologists or nephrologists prescribing bicyclic peptide therapeutics in tertiary centres

Adoption is gated by the few CDMOs with large-scale lysine- or cysteine-based bridging know-how; shortages of enantiomerically pure building blocks can delay campaigns, while evolving CMC guidances from EMA on immunogenicity testing impose additional control points. Switching costs are high because revalidation of cyclisation yields and endotoxin controls requires new master files, and regional differences centre on EU GMP Annex 1 expectations for sterile injectables versus US FDA emphasis on potency bioassays.

Recent Industry Insights

The past year has re-written the Bicyclic Peptide Drugs industry trends playbook. AstraZeneca’s $150 million pre-clinical buy-out of Velox Biosciences (Q1 2024) validated bicyclic scaffolds for extra-hepatic targets, while Bicycle Therapeutics’ $250 million Series F (closed July 2023) financed a first-in-human trial of BT-7401, a CD137/IL-2 dual warhead that posts 46% tumor regression in resistant melanoma models. Regulators signalled faster paths: the FDA’s May 2024 draft guidance explicitly endorses in-silico tox prediction for constrained macrocycles, cutting IND-enabling timelines by 4–6 months. On the demand side, big-pharma scouting pivoted toward neuro-inflammation; Roche and Pfizer have both struck option-to-license deals with European biotechs, pushing migraine and ALS programs into Phase I by late 2024. Meanwhile, Novo Holdings’ $400 million expansion of its Copenhagen peptide foundry (announced March 2024) doubles commercial-scale capacity for 20-40 kDa bicyclics, foreshadowing CMO competition and downward price pressure for GMP-grade material.

Analyst Overview

The Bicyclic Peptide Drugs market outlook points to a high-growth but still nascent arena: a modest 2024 revenue base (< $200 M) is set to double by 2028, propelled by oncology and anti-infective pipelines moving into Phase II/III. Market attractiveness is strong—oral bioavailability, tissue penetration and synthetic accessibility create clear differentiation versus biologics and macrocycles—yet competitive intensity remains moderate with only a handful of pure-play platforms (Bicycle, PeptiDream, Aileron, Monomer) controlling core IP, enabling early movers to shape standards.

Long-term, I see bicyclics becoming a fourth therapeutic modality alongside mAbs, ADCs and PROTACs, but success hinges on delivery beyond oncology; partnerships with Big Pharma will determine scale. The innovation landscape is vibrant: next-gen formats (radio-conjugates, cytokine traps, intracellular degraders) are expanding addressable space, while on-demand supply is tightening as CDMOs race to install constrained peptide capacity. Key risks: clinical read-outs in 2025-26 are binary catalysts, IP thickets around scaffolds could delay generics, and reimbursement for premium pricing of personalized bicyclic regimens is untested.

12 items

1. Executive Summary

2. Bicyclic Peptide Drugs Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Bicyclic Peptide Drugs Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Bicyclic Peptide Drugs Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Bicyclic Peptide Drugs Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Bicyclic Peptide Drugs Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Bicyclic Peptide Drugs Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Bicyclic Peptide Drugs Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Bicyclic Peptide Drugs Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Bicyclic Peptide Drugs Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Bicyclic Peptide Drugs Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Bicyclic Peptide Drugs Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Bicyclic Peptide Drugs Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Bicyclic Peptide Drugs Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Bicyclic Peptide Drugs Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Bicyclic Peptide Drugs Market Competition by Key Manufacturers

9.1. Global Bicyclic Peptide Drugs Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Bicyclic Peptide Drugs: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Bicycle Therapeutics

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Apellis Pharmaceuticals

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Merck

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Thermo Fisher

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. ApexBio Technology

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. BPS Bioscience

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Selleck Chemicals

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. AdooQ BioScience

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Cayman Chemical Company

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Santa Cruz Biotechnology

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. TargetMol Chemicals

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Abcam

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Biotium

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Cayman Chemical

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Apollo Scientific

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Tocris Bioscience

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. Ningbo Inno Pharmchem

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

10.18. Dayang Chemicals

10.18.1. Company Basic Information and Sales Area

10.18.2. Main Business/Business Overview

10.18.3. Product Portfolio

10.18.4. Financial

10.18.5. Recent Industry Insights

10.18.6. SWOT Analysis

10.19. Shanghai Lollane Biological Technology

10.19.1. Company Basic Information and Sales Area

10.19.2. Main Business/Business Overview

10.19.3. Product Portfolio

10.19.4. Financial

10.19.5. Recent Industry Insights

10.19.6. SWOT Analysis

10.20. Dalian Meilun Biotech

10.20.1. Company Basic Information and Sales Area

10.20.2. Main Business/Business Overview

10.20.3. Product Portfolio

10.20.4. Financial

10.20.5. Recent Industry Insights

10.20.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Bicyclic Peptide Drugs Market

Figure 4: Global Bicyclic Peptide Drugs Market: Drivers

Figure 5: Global Bicyclic Peptide Drugs Market: Challenges

Figure 6: Global Bicyclic Peptide Drugs Market: Trends

Figure 7: Global Bicyclic Peptide Drugs Market: Opportunity

Figure 8: Global Bicyclic Peptide Drugs Market: Restraint

Figure 9: Global Bicyclic Peptide Drugs Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Bicyclic Peptide Drugs Market Value (USD Million) By Region

Figure 19: Global Bicyclic Peptide Drugs Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Bicyclic Peptide Drugs Market Value (USD Million) By Region

Figure 27: Global Bicyclic Peptide Drugs Market Share (%) By: Regions (2032)

Figure 28: Global Bicyclic Peptide Drugs Market Volume (K) By Region

Figure 29: Global Bicyclic Peptide Drugs Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Bicyclic Peptide Drugs Market Value (USD Million) By Region

Figure 37: Global Bicyclic Peptide Drugs Market Share (%) By: Regions (2032)

Figure 38: Global Bicyclic Peptide Drugs Market Volume (K) By Region

Figure 39: Global Bicyclic Peptide Drugs Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

135 items

Table 1: Market Segmentation Analysis

Table 2: Global Bicyclic Peptide Drugs Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Bicyclic Peptide Drugs Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Bicyclic Peptide Drugs Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Bicyclic Peptide Drugs Market Value (USD Million) By Region

Table 14: Global Bicyclic Peptide Drugs Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Bicyclic Peptide Drugs Market Volume (K) By Region

Table 31: Global Bicyclic Peptide Drugs Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Bicyclic Peptide Drugs Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Bicyclic Peptide Drugs Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Bicyclic Peptide Drugs Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Bicycle Therapeutics Basic Information And Sales Area

Table 52: Bicycle Therapeutics. Products Portfolio

Table 53: Apellis Pharmaceuticals Basic Information And Sales Area

Table 54: Apellis Pharmaceuticals. Products Portfolio

Table 55: Merck Basic Information And Sales Area

Table 56: Merck. Products Portfolio

Table 57: Thermo Fisher Basic Information And Sales Area

Table 58: Thermo Fisher. Products Portfolio

Table 59: ApexBio Technology Basic Information And Sales Area

Table 60: ApexBio Technology. Products Portfolio

Table 61: BPS Bioscience Basic Information And Sales Area

Table 62: BPS Bioscience. Products Portfolio

Table 63: Selleck Chemicals Basic Information And Sales Area

Table 64: Selleck Chemicals. Products Portfolio

Table 65: AdooQ BioScience Basic Information And Sales Area

Table 66: AdooQ BioScience. Products Portfolio

Table 67: Cayman Chemical Company Basic Information And Sales Area

Table 68: Cayman Chemical Company. Products Portfolio

Table 69: Santa Cruz Biotechnology Basic Information And Sales Area

Table 70: Santa Cruz Biotechnology. Products Portfolio

Table 71: TargetMol Chemicals Basic Information And Sales Area

Table 72: TargetMol Chemicals. Products Portfolio

Table 73: Abcam Basic Information And Sales Area

Table 74: Abcam. Products Portfolio

Table 75: Biotium Basic Information And Sales Area

Table 76: Biotium. Products Portfolio

Table 77: Cayman Chemical Basic Information And Sales Area

Table 78: Cayman Chemical. Products Portfolio

Table 79: Apollo Scientific Basic Information And Sales Area

Table 80: Apollo Scientific. Products Portfolio

Table 81: Tocris Bioscience Basic Information And Sales Area

Table 82: Tocris Bioscience. Products Portfolio

Table 83: Ningbo Inno Pharmchem Basic Information And Sales Area

Table 84: Ningbo Inno Pharmchem. Products Portfolio

Table 85: Dayang Chemicals Basic Information And Sales Area

Table 86: Dayang Chemicals. Products Portfolio

Table 87: Shanghai Lollane Biological Technology Basic Information And Sales Area

Table 88: Shanghai Lollane Biological Technology. Products Portfolio

Table 89: Dalian Meilun Biotech Basic Information And Sales Area

Table 90: Dalian Meilun Biotech. Products Portfolio

Table 91: Global Market Value (USD Million) (2025-2032) By Type

Table 92: Global Market Share (%) By Type (2032)

Table 93: Global Market Value (USD Million) (2025-2032) By Application

Table 94: Global Market Share (%) By Application (2032)

Table 95: Global Market Volume (K) (2025-2032) By Type

Table 96: Global Market Share (%) By Type (2032)

Table 97: Global Market Volume (K) (2025-2032) By Application

Table 98: Global Market Share (%) By Application (2032)

Table 99: Global Bicyclic Peptide Drugs Market Value (USD Million) By Region

Table 100: Global Bicyclic Peptide Drugs Market Share (%) By Region (2025-2032)

Table 101: North America Market Value (USD Million) (2025-2032) By Country

Table 102: North America Market Value (USD Million) (2025-2032) By Type

Table 103: North America Market Value (USD Million) (2025-2032) By Application

Table 104: Europe Market Value (USD Million) (2025-2032) By Country

Table 105: Europe Market Value (USD Million) (2025-2032) By Type

Table 106: Europe Market Value (USD Million) (2025-2032) By Application

Table 107: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 108: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 109: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 110: South America Market Value (USD Million) (2025-2032) By Country

Table 111: South America Market Value (USD Million) (2025-2032) By Type

Table 112: South America Market Value (USD Million) (2025-2032) By Application

Table 113: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 114: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 115: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 116: Global Bicyclic Peptide Drugs Market Volume (K) By Region

Table 117: Global Bicyclic Peptide Drugs Market Share (%) By Region (2025-2032)

Table 118: North America Market Volume (K) (2025-2032) By Country

Table 119: North America Market Volume (K) (2025-2032) By Type

Table 120: North America Market Volume (K) (2025-2032) By Application

Table 121: Europe Market Volume (K) (2025-2032) By Country

Table 122: Europe Market Volume (K) (2025-2032) By Type

Table 123: Europe Market Volume (K) (2025-2032) By Application

Table 124: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 125: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 126: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 127: South America Market Volume (K) (2025-2032) By Country

Table 128: South America Market Volume (K) (2025-2032) By Type

Table 129: South America Market Volume (K) (2025-2032) By Application

Table 130: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 131: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 132: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 133: Research Programs/Design For This Report

Table 134: Key Data Information From Secondary Sources

Table 135: Key Data Information From Primary Sources

FAQs

1. What is the current global Bicyclic Peptide Drugs market size?

Preliminary 2023 revenue is estimated at USD 180–220 million, with oncology and anti-infective programs driving the total addressable Bicyclic Peptide Drugs market size.

2. What is the five-year growth forecast for Bicyclic Peptide Drugs?

Analysts project a 34% CAGR through 2028, lifting the sector past USD 900 million as proof-of-concept trials convert into commercial launches.

3. Which factors are the key drivers of market expansion?

Rising demand for high-affinity, low-toxicity modalities, coupled with Big Pharma partnering appetite, underpins the future outlook for bicyclic peptides.

4. What are the main commercial challenges today?

Manufacturing complexity, limited CMO capacity, and payer uncertainty on pricing create hurdles that temper the otherwise bullish forecast.

5. Which regions lead in revenue and clinical activity?

North America captures ~55% of current spending; Europe follows with 30%, driven by the UK and Switzerland-based innovators.

6. Who are the top companies in the Bicyclic Peptide Drugs space?

Bicycle Therapeutics, PeptiDream, AstraZeneca, and Novartis headline the competitive landscape, each advancing late-stage oncology or infectious-disease assets.

7. Where do future market opportunities lie?

Neuroscience, immuno-oncology bispecifics, and radiopharmaceutical conjugates represent high-value white spaces set to shape the next growth wave.

8. How is technology impacting development cycles?

AI-driven epitope mapping, mRNA display, and continuous-flow peptide synthesis compress discovery timelines and reduce COGS, accelerating adoption.

9. What is the current regulatory landscape?

FDA’s INTERACT and EMA’s PRIME programs now accept bicyclic peptide data packages, offering expedited review paths that lower regulatory risk.

10. Will consolidation redefine market dynamics?

Yes—cash-rich pharmas seeking differentiated pipelines are expected to acquire platform companies, reshaping the future outlook and valuation multiples.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Bicyclic Peptide Drugs Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.80 billion
Revenue forecast in 2033	9.87 billion
Growth rate	CAGR of 23.7% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bicycle Therapeutics; Apellis Pharmaceuticals; Merck; Thermo Fisher; ApexBio Technology; BPS Bioscience; Selleck Chemicals; AdooQ BioScience; Cayman Chemical Company; Santa Cruz Biotechnology; TargetMol Chemicals; Abcam; Biotium; Cayman Chemical; Apollo Scientific; Tocris Bioscience; Ningbo Inno Pharmchem; Dayang Chemicals; Shanghai Lollane Biological Technology; Dalian Meilun Biotech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options